MISSION STATEMENT:
To stimulate improvement in quality of life for people living with ALS/MND, scientific innovation and exchange of information.
The International Symposium on ALS/MND is a unique annual event which brings together leading international researchers and health and social care professionals to present and debate key innovations in their respective fields.

The Symposium is planned as two parallel meetings, one on biomedical research and the other on advances in the care and management of people affected by ALS/MND. Joint sessions consider issues of mutual concern, challenging current views and practice.

ORGANISER OF THE SYMPOSIUM:
Motor Neurone Disease Association
PO Box 246
Northampton NN1 2PR, UK
tel: (+) 44 1604 611845 or 611822
fax: (+) 44 1604 611858
email: symposium@mndassociation.org
website: www.mndassociation.org

The 20th International Symposium on ALS/MND is being held in co-operation with
The International Alliance of ALS/MND Associations
Secretariat: PO Box 246, Northampton NN1 2PR, UK
tel: (+) 44 1604 611821 fax: (+) 44 1604 624726
email: alliance@alsmndalliance.org

HOST FOR THE SYMPOSIUM:
Deutsche Gesellschaft für Muskelkranke e.V. (DGM)
(German Neuromuscular Diseases Association)
Im Moos 4
79112 Freiburg, Germany
tel: +49 (0)7665 94470
fax: +49 (0)7665 944720
email: info@dgm.org
website: www.dgm.org

The International Symposium on ALS/MND is firmly established as the premier forum for those interested in improving care, understanding disease pathogenesis and developing novel treatments for ALS/MND. We have maintained our traditional structure of parallel sessions for basic science and more clinical topics, with opening and closing joint sessions, which we anticipate will be of interest to the broad range of delegates that this meeting attracts.

The goal of the Symposium Programme Committee has been to attract speakers of the highest international calibre, who will give presentations on a range of topical themes. We are grateful to those who have accepted invitations to speak at this year’s event. We are also indebted to ALS/MND investigators around the world who have once again submitted a record number of abstracts. Such is the breadth of expertise and quality of research, that the Programme Committee is confident that the 20th International Symposium on ALS/MND will be a stimulating and vibrant event, providing delegates with a state-of-the-art-review of the latest progress in research and clinical practice.

We look forward to seeing you in Berlin.

Pamela Shaw, MD FRCP FMedSci
Programme Committee Chair

Welcome from the Deutsche Gesellschaft für Muskelkranke e.V. (DGM)

After hosting this event for the first time in 1998 in Munich, the DGM is proud and honoured to have the privilege once more of bringing together the world’s leading ALS/MND experts.

The Symposium boasts clinical, as well as scientific sessions, so that experts in both the scientific and the clinical fields can share their latest findings and examples of good practice.

For the last 40 years the DGM has been committed, not only on promoting research on ALS/MND, but also on transferring research results into treatments and care for people living with the disease and their families.

The international exchange of knowledge and strategies is essential to provide the best possible care for people living with the disease. We want to play a key role in ending the disease, and by hosting the 20th International Symposium, we hope to bring closer the day when no one has to live with MND’s devastating impact.

We look forward to welcoming you to the 20th International Symposium on ALS/MND as well as the 17th Annual Meeting of the International Alliance of ALS/MND Associations 2009 in Berlin.

Berlin, Germany’s capital city is dynamic and creative. As a rejuvenated and vibrant city, Berlin has much to offer both business travelers and tourists. Whether you wish to explore the history through architecture, listen to yourself in culture through arts and entertainment or enjoy the shopping district, Berlin has it all.

Horst Ganter
Chief Executive
Deutsche Gesellschaft für Muskelkranke e.V.
### SATELLITE MEETINGS AND EVENTS

<table>
<thead>
<tr>
<th>Date</th>
<th>Meeting</th>
<th>Venue</th>
<th>Time</th>
<th>Contact</th>
</tr>
</thead>
<tbody>
<tr>
<td>4 December</td>
<td>Board of Directors Meeting, International Alliance of ALS/MND Associations</td>
<td>Salon 9 Tallinn</td>
<td>09.00 – 10.00</td>
<td>For further information on all satellite meetings, please contact: K Lasserre Yorke, USA</td>
</tr>
<tr>
<td>5 December</td>
<td>Annual General Meeting and MUNIX Study Group</td>
<td>Salon 21 Dublin</td>
<td>07.30 – 08.30</td>
<td>For further information on this meeting, please contact: F Murphy, USA</td>
</tr>
<tr>
<td>6 December</td>
<td>17th Annual Meeting of the International Alliance of ALS/MND Associations</td>
<td>Salon 17 Riga</td>
<td>08.30 – 09.00</td>
<td>N Lessard, USA</td>
</tr>
<tr>
<td>7 December</td>
<td>ALS/MND Associations International Alliance of ALS/MND Associations</td>
<td>Salon 17 Riga</td>
<td>09.00 – 10.00</td>
<td>For further information on this meeting, please contact: M Murphy, USA</td>
</tr>
</tbody>
</table>

### ALLIED PROFESSIONALS’ FORUM – PROGRAMME

#### Sunday 2 November

#### 9.00 – 10.00 Morning/Introduction

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker/Contact</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.10</td>
<td>Inviting relatives in a multidisciplinary ALS clinic</td>
<td>M Lessard Yorke, USA</td>
</tr>
<tr>
<td>09.30</td>
<td>The development and implementation of a multi-agency multidisciplinary care network for people living with motor neuron disease in East and North Harford, UK</td>
<td>D Pickard, UK</td>
</tr>
<tr>
<td>09.50</td>
<td>Collaborative care in motor neuron disease in Victoria, Australia</td>
<td>S Matterson, Australia</td>
</tr>
<tr>
<td>10.30</td>
<td>Dilemmas and integrity of medical professionals</td>
<td>M Opine, Japan</td>
</tr>
<tr>
<td>10.50</td>
<td>Occupational therapy and physiotherapy at an Irish tertiary ALS centre: An audit to review care links with community care services</td>
<td>S Frey, Ireland</td>
</tr>
</tbody>
</table>

#### 10.50 – 11.20 Refreshment Break

#### 11.20 – 12.00 Pre-Symptomatic testing for familial ALS – The pre-fALS experience

<table>
<thead>
<tr>
<th>Speaker/Contact</th>
</tr>
</thead>
<tbody>
<tr>
<td>S Gronka, USA</td>
</tr>
</tbody>
</table>

#### 12.00 – 13.00 Lunch

#### 13.20 – 14.00 End-of-life decisions and advance care directives in motor neuron disease: Evidence based guidelines for best practice

<table>
<thead>
<tr>
<th>Speaker/Contact</th>
</tr>
</thead>
<tbody>
<tr>
<td>B Curr, Ireland</td>
</tr>
</tbody>
</table>

#### 14.10 – 14.50 Providing equipment for people with MND – Thinking outside the box!

<table>
<thead>
<tr>
<th>Speaker/Contact</th>
</tr>
</thead>
<tbody>
<tr>
<td>C Birks, Australia</td>
</tr>
</tbody>
</table>

#### 14.50 – 15.20 Promoting upright seating and home-based care for people living with MND

<table>
<thead>
<tr>
<th>Speaker/Contact</th>
</tr>
</thead>
<tbody>
<tr>
<td>M Ogino, USA</td>
</tr>
</tbody>
</table>

#### 15.20 – 16.00 Role for developing familial ALS: What family members know and what they need to know

<table>
<thead>
<tr>
<th>Speaker/Contact</th>
</tr>
</thead>
<tbody>
<tr>
<td>M Polak, USA</td>
</tr>
</tbody>
</table>

#### 16.00 – 16.30 Professional practice – local knowledge/global impact

<table>
<thead>
<tr>
<th>Speaker/Contact</th>
</tr>
</thead>
<tbody>
<tr>
<td>S Grevea, USA</td>
</tr>
</tbody>
</table>

#### 16.40 – 17.00 Summary and Close

<table>
<thead>
<tr>
<th>Speaker/Contact</th>
</tr>
</thead>
<tbody>
<tr>
<td>K Mitchell, Canada</td>
</tr>
</tbody>
</table>

---

Registration for the Allied Professionals’ Forum is £85 to health and social care professionals who have registered for the International Symposium, and £100 for those attending this day only.

This Event has been kindly sponsored by ALS Hope Foundation.

---

For further information on all Alliances meetings, please contact: alliance@alsmndalliance.org
SESSION 1 JOINT OPENING SESSION
08.30 - 08.40 Welcome – P Bowes (UK)
08.40 - 09.00 Welcome – German Government Representative (TBC)

SESSION 2A PROTEINOPATHIES
08.40 - 08.50 Welcome – German Government Representative (TBC)
09.00 - 10.00 Overview of neurodegenerative proteinopathies – M Neumann (Germany)
10.00 - 10.15 Role of TDP-43 in disease pathogenesis – M Spillantini (UK)
10.15 - 11.00 Interaction partners for misfolded SOD1 – A Walker (Australia)
11.00 - 11.15 Factors underlying end-of-life decisions in ALS – P Callagher (UK)
11.15 - 11.30 Medication in the last days of life of MND/ALS – S Sorg (Germany)
11.30 - 11.45 Factors exacerbating end of life decisions in ALS patients – P Andersen (Sweden)
11.45 - 11.50 The roles of RNA editing and calcium-permeable AMPA receptors in motor neuron disease – W Camu (France)
11.50 - 12.00 Chromogranin variants as risk factor and modifier of disease onset for Amyotrophic Lateral Sclerosis – J Connor (USA)
12.00 - 12.15 Cellular impact of HFE H63D allelic variant on ALS – J-P Julien (Canada)
12.15 - 12.30 The utility of single-fiber electromyography in the differential diagnosis of ALS and cervical spondylosis – W Boekestein (Netherlands)
12.30 - 12.45 Modified incremental motor unit estimation in a rat model for ALS – F Baas (Netherlands)
12.45 - 13.00 New diagnostic criteria for Primary Lateral Sclerosis: a prospective validation – F Brugman (Netherlands)
13.00 - 13.15 A prospective and blind study of the triple stimulation technique in the diagnosis of ALS – W Camu (France)
13.15 - 13.30 Rapid validation of ALS biomarkers: an integrated approach – W Camu (France)
13.45 - 14.00 Multicenter longitudinal study on coordination of patients with ALS: a longitudinal natural history study of subjects with ALS – W Camu (France)
14.00 - 14.15 MRI-based neuroimaging as a surrogate maker in ALS and other motor neuron disorders: prospects and pitfalls – J Komarck (Germany)
14.15 - 14.30 MRI-based neuroimaging as a surrogate maker in ALS and other motor neuron disorders: prospects and pitfalls – J Komarck (Germany)
14.30 - 14.45 Microvascular changes in the dog’s cerebral cortex cause microvascular PET signal changes in ALS – B Kleine (Netherlands)
14.45 - 15.00 Medication in the last days of life of MND/ALS – S Sorg (Germany)
15.00 - 15.15 MRI-based neuroimaging as a surrogate maker in ALS and other motor neuron disorders: prospects and pitfalls – J Komarck (Germany)
15.15 - 15.30 Tackling the challenges of ALS from a family perspective – M Neumann (Germany)

SESSION 3B CLINICAL PHENOTYPES & DISEASE PROGRESSION
14.45 - 15.00 The utility of single-fiber electromyography in the differential diagnosis of ALS and cervical spondylosis – W Camu (France)
15.00 - 15.15 Understanding the pathophysiology of ALS – M Romani (Australia)
15.15 - 15.30 The utility of single-fiber electromyography in the differential diagnosis of ALS and cervical spondylosis – W Camu (France)
15.30 - 16.00 The roles of RNA editing and calcium-permeable AMPA receptors in motor neuron disease – W Camu (France)
16.00 - 16.15 White-gross expression profiling in motor cortex and spinal cord of patients with Amyotrophic Lateral Sclerosis – L Keegan (UK)
16.15 - 16.30 The new electrodiagnostic criteria for ALS: a prospective validation – F Brugman (Netherlands)
16.30 - 16.45 MRI-based neuroimaging as a surrogate maker in ALS and other motor neuron disorders: prospects and pitfalls – J Komarck (Germany)
16.45 - 17.00 Multicenter longitudinal study on coordination of patients with ALS: a longitudinal natural history study of subjects with ALS – W Camu (France)
17.00 - 17.15 A prospective and blind study of the triple stimulation technique in the diagnosis of ALS – W Camu (France)
17.15 - 17.30 The utility of single-fiber electromyography in the differential diagnosis of ALS and cervical spondylosis – W Camu (France)
17.30 - 17.45 Understanding the pathophysiology of ALS – M Romani (Australia)

SESSION 4A FUNCTIONAL GENOMICS
14.45 - 15.00 The utility of single-fiber electromyography in the differential diagnosis of ALS and cervical spondylosis – W Camu (France)
15.00 - 15.15 Understanding the pathophysiology of ALS – M Romani (Australia)
15.15 - 15.30 The utility of single-fiber electromyography in the differential diagnosis of ALS and cervical spondylosis – W Camu (France)
15.30 - 16.00 The utility of single-fiber electromyography in the differential diagnosis of ALS and cervical spondylosis – W Camu (France)
16.00 - 16.15 White-gross expression profiling in motor cortex and spinal cord of patients with Amyotrophic Lateral Sclerosis – L Keegan (UK)
16.15 - 16.30 The new electrodiagnostic criteria for ALS: a prospective validation – F Brugman (Netherlands)
16.30 - 16.45 MRI-based neuroimaging as a surrogate maker in ALS and other motor neuron disorders: prospects and pitfalls – J Komarck (Germany)
16.45 - 17.00 Multicenter longitudinal study on coordination of patients with ALS: a longitudinal natural history study of subjects with ALS – W Camu (France)
17.00 - 17.15 A prospective and blind study of the triple stimulation technique in the diagnosis of ALS – W Camu (France)
17.15 - 17.30 The utility of single-fiber electromyography in the differential diagnosis of ALS and cervical spondylosis – W Camu (France)
17.30 - 17.45 Understanding the pathophysiology of ALS – M Romani (Australia)
SESSION 6A MOTOR NEURON BIOLOGY

11.30 - 12.00
Sonic hedgehog signalling and the control of motor neuron and ventral interneuron generation – J Briscoe (UK)

12.00 - 12.30
From motor cortex to muscle: species differences in motor pathways – R Lemon (UK)

SESSION 6B CLINICAL TRIALS & TRIAL DESIGN

11.30 - 11.45
Ceftriaxone in ALS: results of stages 1 and 2 of an adaptive design safety, pharmacokinetic and efficacy trial – M Cudkowicz (USA)

11.45 - 12.00
KNS-760704-CL201, Part 1: A 12-week phase 2 study of the safety, tolerability and clinical effects of KNS 760704 in ALS subjects – M Cudkowicz (USA)

12.00 - 12.15
STAR trial: sub-analysis of an international, multi-center, placebo-controlled study of AVP-923 (dextromethorphan/quinidine) for the treatment of pseudobulbar affect (PBA) in Amyotrophic Lateral Sclerosis (ALS) patients – B Brooks (USA)

12.15 - 12.30
Regulatory documents management platform: efficiency, scalability, regulatory compliance and standardization in clinical trials in ALS – A Sherman (USA)

12.30 - 12.45
The effect of inclusion criteria on outcomes: interpreting results in historical placebo controlled trials – J Katz (USA)

SESSION 7A EMERGING DISEASE MODELS

14.00 - 14.30
IPS cells: steps toward an in-vitro model of ALS – T Ramesh (UK)

14.30 - 14.45
Evaluation of functional motor neurons derived from induced pluripotent stem cells (iPS) and human embryonic stem cells (hESC) – M Wiedau-Pazos (USA)

14.45 - 15.00
A zebrafish model of ALS shows induction of early cellular stress – T Ramesh (UK)

15.00 - 15.15
Functional characterization of mutant TDP-43 in zebrafish – E Kabashi (Canada)

15.15 - 15.30
TDP-43 toxicity in the chick embryo model system – V Tripathi (UK)

SESSION 7B SPIRITUAL CARE AND MEANING IN LIFE

14.00 - 14.30
Meaning of life in ALS: empirical data and clinical relevance – M Fegg (Germany)

14.30 - 15.00
Evidence based spiritual care in ALS: fact or fiction – T Roser (France)

15.00 - 15.15
Spirituality and faith: means for coping with the effects of ALS/MND – M O’Brien (UK)

15.15 - 15.30
Managing death in ALS/MND: identifying caregiver perspectives of the final days of life – R Ray (Australia)

SESSION 7C FUS MUTATIONS IN FAMILIAL ALS

14.00 - 14.10
Mutations in the RNA binding gene FUS cause familial ALS – C Vance (UK)

14.10 - 14.30
FUS mutations in a large series of sporadic and familial ALS - A Chiò (Italy)

14.30 - 14.40
Identification of FUS/TLS gene mutations in a cohort of Italian ALS patients – N Ticozzi (Italy & USA)

14.40 - 14.50
Novel FUS mutations in a large cohort of ALS patients – J Yan (USA)

14.50 - 15.00
FUS mutations in Belgian familial Amyotrophic Lateral Sclerosis patients – P Van Damme (Belgium)

15.00 - 15.10
Mutations of FUS/TLS in a large Chinese pedigree with Amyotrophic Lateral Sclerosis – H Shang (China)

15.10 - 15.20
Screening for FUS mutations in Amyotrophic Lateral Sclerosis – C Hewitt (UK)

15.20 - 15.30
Mutation screening in TLS gene in patients with MND – N Revesz (France)

POSTER SESSION

08.30 - 11.00
Poster Session

POSTER THEMES

● Human cell biology and pathology
● Genetics
● Epidemiology
● In vitro experimental models
● In vivo experimental models
● Improving diagnosis, prognosis and disease progression
● Imaging, electrophysiology and markers of disease progression
● Respiratory and nutritional management
● Therapeutic strategies
● Scientific and clinical work in progress & Care practice

WEDNESDAY 9 DECEMBER

SESSION 5 POSTER SESSION

08.30 - 11.00
Poster Session

SESSION 6B CLINICAL TRIALS & TRIAL DESIGN

11.30 - 11.45
Ceftriaxone in ALS: results of stages 1 and 2 of an adaptive design safety, pharmacokinetic and efficacy trial – M Cudkowicz (USA)

11.45 - 12.00
KNS-760704-CL201, Part 1: A 12-week phase 2 study of the safety, tolerability and clinical effects of KNS 760704 in ALS subjects – M Cudkowicz (USA)

12.00 - 12.15
STAR trial: sub-analysis of an international, multi-center, placebo-controlled study of AVP-923 (dextromethorphan/quinidine) for the treatment of pseudobulbar affect (PBA) in Amyotrophic Lateral Sclerosis (ALS) patients – B Brooks (USA)

12.15 - 12.30
Regulatory documents management platform: efficiency, scalability, regulatory compliance and standardization in clinical trials in ALS – A Sherman (USA)

12.30 - 14.00
LUNCH

14.03 - 14.20
Mutations in the RNA binding gene FUS cause familial ALS – T Ramesh (UK)

14.20 - 14.30
FUS mutations in a large series of sporadic and familial ALS - A Chiò (Italy)

14.30 - 14.40
Identification of FUS/TLS gene mutations in a cohort of Italian ALS patients – N Ticozzi (Italy & USA)

14.40 - 14.50
Novel FUS mutations in a large cohort of ALS patients – J Yan (USA)

14.50 - 15.00
FUS mutations in Belgian familial Amyotrophic Lateral Sclerosis patients – P Van Damme (Belgium)

15.00 - 15.10
Mutations of FUS/TLS in a large Chinese pedigree with Amyotrophic Lateral Sclerosis – H Shang (China)

15.10 - 15.20
Screening for FUS mutations in Amyotrophic Lateral Sclerosis – C Hewitt (UK)

15.20 - 15.30
Mutation screening in TLS gene in patients with MND – N Revesz (France)
SESSION 8A PROTEIN REGULATION AND DEGRADATION

16.30 - 16.45
A. Otomo (Japan)
Missense mutations in the Als2 gene – pathogenesis for motor neuron diseases caused by endosomal localization of Als2 underlies the systemic disease – loss from skeletal muscle upon denervation and A. Otomo (Japan)

16.45 - 17.00
I. Katona (USA)
ALS outreach services – F Goldberg (Canada)
M Ogino (Japan)
S Chua (Canada)
– F Goldberg (Canada)
M O’Brien (UK)

17.00 - 17.15
A caring approach to ALS care – B Poirier (Canada)

17.15 - 17.30
P. Mura (Canada)

SESSION 8B COGNITIVE CHANGE

16.30 - 16.45
Validation of the Penn State brief exam of frontal and temporal dysfunction syndromes in Amyotrophic Lateral Sclerosis: application of Guilford’s Structure of intellect theory – Lateral Sclerosis: application of Guilford’s Structure of intellect theory – Lateral Sclerosis: application of Guilford’s Structure of intellect theory – C Flaherty-Craig (USA)

16.45 - 17.00
Early verbal fluency deficits predict cognitive impairment in ALS – J Phukan (Ireland)

17.00 - 17.15
Validation of a brief cognitive screening exam for ALS – D Neary (UK)

17.15 - 17.30
Anti-saccade paradigm in the cognitive frontal assessment of Amyotrophic Lateral Sclerosis – D Neary (UK)

SESSION 8C INTERNATIONAL PERSPECTIVES ON CARE MANAGEMEN

16.30 - 16.45
Enhancing speech during BiPAP use – F Goldberg (USA)

16.45 - 17.00
The survey report of ALS physicians in Japan – F Goldberg (USA)

17.00 - 17.15
ALS outreach services – F Goldberg (Canada)
M Ogino (Japan)
S Chua (Canada)
– F Goldberg (Canada)
M O’Brien (UK)

17.15 - 17.30
A caring approach to ALS care – B Poirier (Canada)

SESSION 10B RESPIRATORY MANAGEMENT

10.30 - 10.45
Analysis of annual transport from in situ screens to real time in vivo assays – G Sciarra (UK)

10.45 - 11.00
Respiratory exercises in Amyotrophic Lateral Sclerosis (REALS) – F Pinto (Portugal)

11.00 - 11.15
Home initiation of non-invasive ventilation for respiratory failure – M Johnson (USA)

11.15 - 11.30
Neuroimaging of genes with a function in neurite outgrowth and synapse formation to make rational decisions in the ALS/gag mouse model of Amyotrophic Lateral Sclerosis – A. Hendrich (UK)

11.30 - 11.45
A role of BDNF in HIBM/ALS amyotrophy – R Onders (USA)

11.45 - 12.00
O2 deprivation-induced axonal RNA transport: roles in motor neuron function and disease progression and survival in a murine model of Amyotrophic Lateral Sclerosis – J. M. Jones (USA)

12.00 - 12.15
CD4+CD25+FoxP3+ reglatory T cells infiltration induces early verbal fluency deficits predict cognitive impairment in ALS – D Neary (UK)

12.15 - 12.30
Anti-CD40L monoclonal antibody therapy improves neuroinflammation – S Perrin (USA)

12.30 - 14.00
LUNCH
TRAVEL INFORMATION

For people with a disability it is important to know about the following:

AIRPORTS

Tegel (TXL)
From Tegal Airport (TXL):

Duration Costs Duration Costs
20 min. 23.00 25 min. 15.00
85 min. 20.00 105 min. 12.00
90 min. 22.00 100 min. 20.00
120 min. 27.00 140 min. 25.00
150 min. 31.00 165 min. 27.00
185 min. 35.00 200 min. 30.00
190 min. 40.00 200 min. 35.00

Duration Costs
20 min. 23.00
85 min. 20.00
90 min. 22.00
120 min. 27.00
150 min. 31.00
190 min. 40.00

Shuttle service over 100 lines.

Buses: All new buses are equipped with ramps that can be lowered. These ramps are in the position of the cabin of the bus. With ramps are used in order to transport passengers in wheelchairs.

Trains: The trains consist of modern trains with a low floor, which also have ramps that can be lowered. The trains operate on 10 lines. You can reach a special step that can be used in the cabin of the train by the help of a ramp to move on and off the vehicle. The ramp extends from the middle of the cabin up to the platform or down to the cabin.

The above prices are correct at the time of publication.

Session 11 JOINT CLOSING SESSION
14.00 - 14.20 Symposium Highlights (Econc)
14.20 - 14.40 Symposium Highlights (Biebrau)
14.40 - 15.10 Clinical biomarker use in the clinical investigation of
- EACCME (accepted by AMA)
- RCP London

CME Accreditation is being sought from:
- EACCME (accepted by AMA)
- RCP London

When booking this transport service, please use the keyword “MND Symposium”. The company is picking up and dropping off at all stations to the hospital, business center, and guest houses. On request, also pick up from the hotel.

For more information, please visit: www.Fahrdienst-brauch.de

tel: +49 (0)30 3198010

www.fahrdienst-brauch.de

www.mndassociation.org/organizers/berlin

...an evolving City...

Berlin

...an evolving City...

Berlin has a wealth of splendid architecture including the Reichstag Building, which is an impressive mixed construction of today and yesterday. The building was remodelled by British architect Norman Foster in the 1990s. It features a glass dome, which allows two public access to the parliament building and boasts magnificent views of the

When booking this transport service, please use the keyword “MND Symposium”. The company is picking up and dropping off at all stations to the hospital, business center, and guest houses. On request, also pick up from the hotel.

For more information, please visit: www.Fahrdienst-brauch.de

tel: +49 (0)30 3198010

www.fahrdienst-brauch.de

www.mndassociation.org/organizers/berlin


**VENUE**

Maritim Hotel Berlin  
Stauffenbergstraße 26  
12089 Berlin  
Germany  
tel.: +49 (0)30 2065-0  


Taking advantage of the ALS/MND Symposium special rates:

To reserve accommodation at the venue please email reservierung.ber@maritim.de quoting INTSYMP09 in the subject line with your requirements and dates.

Rates are as follows:

- single room €137.00 per night (including breakfast)
- double room €165.00 per night (including breakfast)

For other Berlin hotels (including wheelchair accessible rooms), search the areas ‘Mitte’ and ‘Tiergarten’. These areas are close to the Maritim Hotel.

GENERAL INFORMATION

26th INTERNATIONAL SYMPOSIUM ON ALS/MND
8-10 DECEMBER 2009, MARITIM HOTEL, BERLIN, GERMANY

Registration Form

Please print in capitals (one form per delegate)

Institution: ________________________________________  Job Title: _________________________________________________________

Mailing Address: (to send confirmation)_____________________________________________________________________________________
__________________________________________________________________________________________________________________

Tel: _______________________ Fax: __________________________   Email: _____________________________________________

REGISTRATION:

(Please note registration fees in £ Sterling)

| Standard Late Onsite | £400 | £450 | £500 | £ ____________________ |

I am a registered Healthcare Professional and wish to attend the Forum on Monday 7 December

Please note there is an additional fee of £85

Yes  No  £ ____________________

Registration fee includes lunch and coffee breaks during the meeting plus the Symposium Dinner on Tuesday 8 December.

Please indicate any special dietary requirements: ____________________________________________________________

If you would like to order tickets for the Symposium dinner, please indicate below:

Number of guest tickets: _________ @  £45 per ticket SYMPOSIUM DINNER  £ ____________________

Visa  Mastercard  Bank Transfer  Cheque/Money order/Bankdraft  Amex  Switch/Maestro

Credit Card Number: Issue No: __________________________

Valid Date: ___/____         Expiry Date: ___/____ Name of Cardholder: _________________________________________________

For your security, please write the last 3 numbers printed on the reverse of your card.

Signature: _________________________________    Date: ___ /____/_____

Send Direct Bank Transfer Please submit this form with your Payments to: payment made out to:
Motor Neurone Disease Association Motor Neurone Disease Association
Lloyds TSB Bank plc P O Box 246 George Row Northampton NN1 2PR

A copy of your bank transfer MUST accompany your Registration Form. Payments should be made gross of bank charges that may be incurred. Please note that CREDIT card charges will be exchanged to £ Sterling at the week's prevailing rate.

I agree to the use of the data on this form for the following purposes:

Purchase/Supplier administration  Disclosure to other ALS/MND organisations

Signed __________________________________________

Webreg/07/9
ALLIED PROFESSIONALS’ FORUM
7 DECEMBER 2009, MARITIM HOTEL, BERLIN, GERMANY

Registration

For this form should be completed by healthcare professionals wishing to attend the Allied Professionals’ Forum online. If attending the International Symposium, registration for the APF will be £85. Please mark the appropriate box on the Symposium registration form.

Please print in capitals

(o means for one person delegate)

Title: __________________________

Last Name: _________________________________________

First Name: ___________________________

Institute: __________________________________________

Job Title: ____________________________________________

Maili ng Address: (to send confirmation)

__________________________________________________________________________

__________________________________________________________________________

Tel: _____________________  Fax: ______________________

E-mail: ____________________________________________

Please indicate any special dietary requirements: _________________________________________

__________________________________________________________________________

__________________________________________________________________________

Registration: Allied Professionals’ Forum Only: £100

PAYMENT METHOD:

Visa  Mastercard  Bank Transfer  Cheque/Money order  Bankdraft

Credit Card Number: ____________________________

Valid Date: ___/____         Expiry Date: ___/____

Name of Cardholder: _________________________________________________

For your security, please write the last 3 numbers printed on the reverse of your card. If Access the 4 numbers printed on the front of the card

Cardholder’s billing address:

__________________________________________________________________________

__________________________________________________________________________

Signature: _________________________________    Date: ___ /____/_____

Send Direct Bank Transfer Please submit this form with your payment to:

Motor Neuron Disease Association

Account No: 02952679 Fax: +44 (0) 1604 611845/611822

Sort Code: 30-96-09 E-mail: symp@mnad association.org

A copy of your bank transfer should be enclosed. If paying by card, please mark the appropriate box on the registration form.

If you would like to take advantage of the early booking discount, please arrive on 5 December and take advantage of the seminar for free. The Allied Professionals’ Forum will take place during the International Symposium.

This form should be completed by Allied Professionals’ wishing to attend the Allied Professionals’ Forum at the International Symposium.

Registration Form

7 December 2009, Maritim Hotel, Berlin, Germany

Motor Neuron Disease Association

Tel: +44 (0) 1604 611845/611822

Lloyds TSB Bank plc P O Box 246 George Row Northampton NN1 2PR

Acco unt No: 02952679 Fax: +44 (0) 1604 611845

Sort Code: 30-96-09